NASDAQ:CYCNCyclerion Therapeutics Stock Price, Forecast & News

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYCN shares have increased by 76.2% and is now trading at $5.11. View which stocks have been most impacted by Coronavirus.

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Cyclerion Therapeutics.

Cyclerion Therapeutics Inc (NASDAQ:CYCN) released its earnings results on Monday, May, 4th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.14. The business had revenue of $1.01 million for the quarter. Cyclerion Therapeutics had a negative return on equity of 96.31% and a negative net margin of 1,917.30%. View Cyclerion Therapeutics' earnings history.

News headlines about CYCN stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cyclerion Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Cyclerion Therapeutics.

Cyclerion Therapeutics saw a decrease in short interest in June. As of June 30th, there was short interest totaling 823,400 shares, a decrease of 16.8% from the June 15th total of 990,200 shares. Based on an average daily trading volume, of 229,800 shares, the short-interest ratio is currently 3.6 days. Currently, 3.6% of the company's shares are sold short. View Cyclerion Therapeutics' Current Options Chain.

Some companies that are related to Cyclerion Therapeutics include Collegium Pharmaceutical (COLL), Atreca (BCEL), Molecular Templates (MTEM), AnaptysBio (ANAB), Ardelyx (ARDX), Legend Biotech (CALT), Kala Pharmaceuticals (KALA), Corbus Pharmaceuticals (CRBP), Syndax Pharmaceuticals (SNDX), Athersys (ATHX), Syros Pharmaceuticals (SYRS), Catalyst Pharmaceuticals (CPRX), Clovis Oncology (CLVS), Crinetics Pharmaceuticals (CRNX) and Viking Therapeutics (VKTX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Ovid Therapeutics (OVID), Galmed Pharmaceuticals (GLMD), Lexicon Pharmaceuticals (LXRX), Onconova Therapeutics (ONTX), Opko Health (OPK), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD) and Agenus (AGEN).

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYCN stock can currently be purchased for approximately $5.11.

Cyclerion Therapeutics has a market capitalization of $141.80 million and generates $4.51 million in revenue each year.

The official website for Cyclerion Therapeutics is www.cyclerion.com.

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]